A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer.

Pathology oncology research : POR Pub Date : 2022-11-07 eCollection Date: 2022-01-01 DOI:10.3389/pore.2022.1610643
Jianmin Zeng, Man Li, Kefan Dai, Bingyu Zuo, Jianhui Guo, Lu Zang
{"title":"A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer.","authors":"Jianmin Zeng,&nbsp;Man Li,&nbsp;Kefan Dai,&nbsp;Bingyu Zuo,&nbsp;Jianhui Guo,&nbsp;Lu Zang","doi":"10.3389/pore.2022.1610643","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> The aim of this study was to construct a glycolysis-related long noncoding RNA (lncRNA) signature to predict the prognosis of patients with gastric cancer (GC). <b>Methods:</b> Glycolysis-related genes were obtained from the Molecular Signatures Database (MSigDB), lncRNA expression profiles and clinical data of GC patients were obtained from The Cancer Genome Atlas database (TCGA). Furthermore, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate Cox regression analysis were used to construct prognostic glycolysis-related lncRNA signature. The specificity and sensitivity of the signature was verified by receiver operating characteristic (ROC) curves. We constructed a nomogram to predict the 1-year, 3-year, and 5-year survival rates of GC patients. Besides, the relationship between immune infiltration and the risk score was analyzed in the high and low risk groups. Multi Experiment Matrix (MEM) was used to analyze glycolysis-related lncRNA target genes. R \"limma\" package was used to analyze the mRNA expression levels of the glycolysis-related lncRNA target genes in TCGA. Gene set enrichment analysis (GSEA) was employed to further explore the biological pathways in the high-risk group and the glycolysis-related lncRNA target gene. <b>Results:</b> A prognostic signature was conducted based on nine glycolysis-related lncRNAs, which are AL391152.1, AL590705.3, RHOXF1-AS1, CFAP61-AS1, LINC00412, AC005165.1, AC110995.1, AL355574.1 and SCAT1. The area under the ROC curve (AUC) values at 1-year, 3-year, and 5-year were 0.765, 0.828 and 0.707 in the training set, and 0.669, 740 and 0.807 in the testing set, respectively. In addition, the nomogram could efficaciously predict the 1-year, 3-year, and 5-year survival rates of the GC patients. Then, we discovered that GC patients with high-risk scores were more likely to respond to immunotherapy. GSEA revealed that the signature was mainly associated with the calcium signaling pathway, extracellular matrix (ECM) receptor interaction, and focal adhesion in high-risk group, also indicated that SBSPON is related to aminoacyl-tRNA biosynthesis, citrate cycle, fructose and mannose metabolism, pentose phosphate pathway and pyrimidine metabolism. <b>Conclusion:</b> Our study shows that the signature can predict the prognosis of GC and may provide new insights into immunotherapeutic strategies.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610643"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676246/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology oncology research : POR","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2022.1610643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The aim of this study was to construct a glycolysis-related long noncoding RNA (lncRNA) signature to predict the prognosis of patients with gastric cancer (GC). Methods: Glycolysis-related genes were obtained from the Molecular Signatures Database (MSigDB), lncRNA expression profiles and clinical data of GC patients were obtained from The Cancer Genome Atlas database (TCGA). Furthermore, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate Cox regression analysis were used to construct prognostic glycolysis-related lncRNA signature. The specificity and sensitivity of the signature was verified by receiver operating characteristic (ROC) curves. We constructed a nomogram to predict the 1-year, 3-year, and 5-year survival rates of GC patients. Besides, the relationship between immune infiltration and the risk score was analyzed in the high and low risk groups. Multi Experiment Matrix (MEM) was used to analyze glycolysis-related lncRNA target genes. R "limma" package was used to analyze the mRNA expression levels of the glycolysis-related lncRNA target genes in TCGA. Gene set enrichment analysis (GSEA) was employed to further explore the biological pathways in the high-risk group and the glycolysis-related lncRNA target gene. Results: A prognostic signature was conducted based on nine glycolysis-related lncRNAs, which are AL391152.1, AL590705.3, RHOXF1-AS1, CFAP61-AS1, LINC00412, AC005165.1, AC110995.1, AL355574.1 and SCAT1. The area under the ROC curve (AUC) values at 1-year, 3-year, and 5-year were 0.765, 0.828 and 0.707 in the training set, and 0.669, 740 and 0.807 in the testing set, respectively. In addition, the nomogram could efficaciously predict the 1-year, 3-year, and 5-year survival rates of the GC patients. Then, we discovered that GC patients with high-risk scores were more likely to respond to immunotherapy. GSEA revealed that the signature was mainly associated with the calcium signaling pathway, extracellular matrix (ECM) receptor interaction, and focal adhesion in high-risk group, also indicated that SBSPON is related to aminoacyl-tRNA biosynthesis, citrate cycle, fructose and mannose metabolism, pentose phosphate pathway and pyrimidine metabolism. Conclusion: Our study shows that the signature can predict the prognosis of GC and may provide new insights into immunotherapeutic strategies.

Abstract Image

Abstract Image

Abstract Image

预测胃癌总生存率的糖酵解相关长链非编码RNA新标记。
背景:本研究旨在构建糖酵解相关的长链非编码RNA (lncRNA)信号来预测胃癌(GC)患者的预后。方法:从分子特征数据库(MSigDB)中获取糖酵解相关基因,从癌症基因组图谱数据库(TCGA)中获取GC患者的lncRNA表达谱和临床数据。此外,采用单因素Cox回归分析、最小绝对收缩和选择算子(LASSO)和多因素Cox回归分析构建预后糖酵解相关的lncRNA特征。通过受试者工作特征(ROC)曲线验证该特征的特异性和敏感性。我们构建了一个nomogram来预测胃癌患者的1年、3年和5年生存率。分析高危组和低危组免疫浸润与风险评分的关系。采用Multi Experiment Matrix (MEM)对糖酵解相关lncRNA靶基因进行分析。采用R“limma”包装分析TCGA中糖酵解相关lncRNA靶基因的mRNA表达水平。采用基因集富集分析(Gene set enrichment analysis, GSEA)进一步探索高危人群及糖酵解相关lncRNA靶基因的生物学通路。结果:基于9个糖酵解相关lncrna进行预后标记,这些lncrna分别为AL391152.1、AL590705.3、RHOXF1-AS1、CFAP61-AS1、LINC00412、AC005165.1、AC110995.1、AL355574.1和SCAT1。1年、3年和5年的ROC曲线下面积(AUC)值在训练集分别为0.765、0.828和0.707,在测试集分别为0.669、740和0.807。此外,nomogram能有效预测胃癌患者的1年、3年、5年生存率。然后,我们发现评分高的GC患者更可能对免疫治疗有反应。GSEA结果显示,该信号主要与高危组钙信号通路、细胞外基质(ECM)受体相互作用和局灶黏附有关,同时表明SBSPON与氨基酰基trna生物合成、柠檬酸循环、果糖和甘露糖代谢、戊糖磷酸途径和嘧啶代谢有关。结论:我们的研究表明,该特征可以预测胃癌的预后,并可能为免疫治疗策略提供新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信